589 related articles for article (PubMed ID: 18349064)
1. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
4. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
6. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
8. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
9. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
14. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
Kim HS; Freedland SJ
Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2.
Gagliano-Jucá T; Burak MF; Pencina KM; Li Z; Edwards RR; Travison TG; Basaria S
J Clin Endocrinol Metab; 2018 Oct; 103(10):3900-3908. PubMed ID: 30032274
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
Collier A; Ghosh S; McGlynn B; Hollins G
Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
[TBL] [Abstract][Full Text] [Related]
19. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
